Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma

Haematologica

Volumn 89, Issue 12, 2004, Pages 1428-1433

  Magill, Laura ^a   Lynas, John ^a   Morris, Trenn C M ^a   Walker, Brian ^a   Irvine, Alexandra E ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Inhibitors; Leukemia; Proteasome; Proteolytic activity

Indexed keywords

BCR ABL PROTEIN; BUFFER; PEPTIDE; PROTEASOME; PROTEASOME INHIBITOR; REGULATOR PROTEIN;

APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN; CELL STRAIN HL 60; CELL STRAIN U266; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; EXTRACTION; FLUORESCENCE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; MYELOMA CELL; PROTEIN DEGRADATION;

APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; EDETIC ACID; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; LEUCINE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PEPSTATINS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS; SULFONES; TRANSFECTION;

EID: 10444224552     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Brooks P, Fuertes G, Murray RZ, Bose S, Knecht E, Rechsteiner MC, et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 2000;346:155-61.
2. Elliott P, Ross JS. The proteasome. Am J Clin Path 2001;116:637-46.
3. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44.
4. Rivett AJ, Bose S, Pemberton AJ, Brooks P, Onion D, Shirley D, et al. Assays of proteasome activity in relation to aging. Exp Gerontol 2002;37:1217-22.
5. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor induced apoptosis: accumulation of wt p53, p21 WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000;14:1276-83.
6. Kumatori, A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, et al. Abnormally high expression of proteasomes in leukaemic cells. Proc Nat Acad Sci USA 1990;87:7071-5.
7. Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset JM, Dumont J, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999;105:752-7.
8. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
9. Richardson PG, Barlogie B, Berenson J, Singhal, S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
10. Rodgers KJ, Dean RT. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 2003;35:716-27.
11. Dahlmann B, Ruppert T, Kuehn L, Merforth S, Kloetzel PM. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 2000;303:643-53.
12. Farout L, Lamare MC, Cardozo C, Harrisson M, Briand Y, Briand M. Distribution of proteasomes and the five proteolytic activites in rat tissues. Arch Biochem Biophys 2000;2:207-12.
13. Orlowski M. The multi catalytic proteinase complex: a major extralysosomal proteolytic system. Biochemistry 1990;29:10289-97.
14. Orlowski M, Cardozo C, Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 1993;32:1563-72.
15. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class1 molecules. Cell 1994;78:761-71.
16. Arendt CS, Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active site formation. Proc Nat Acad Sci USA 1997;94:7156-61.
17. Pierce A, Owen-Lynch PJ, Spooncer E, Dexter TM, Whetton AD. p210 Bcr-Abl expression in a primitive haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene 1998;17:667-72.
18. English D, Anderson BR. Single step separation of red blood cells, granulocytes and mononuclear leukocytes on discontinuous density gradient of Ficoll-Hypaque. J Immunol Meth 1974;5:249-52.
19. Lynas J, Harriott P, Healy A, Mc Keryey A, Walker B. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tripeptidyl α-keto aldehydes (glyoxals). Bioorg Med Chem Lett 1998;8:373-8.
20. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem 1998;273:2926-30.
21. Adams J, Palombella VJ, Sausville E, Johnson J, Destree A, Lazurus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumouragents. Cancer Res 1999;59:2615-22.
22. Drexler HG, Mac Leod RAF, Dirks WG. Cross-contamination: HS-Sultan is nota myeloma but a Burkitt lymphoma cell line. Blood 2001;98:3495-6.
23. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, et al. Phase I study of bortezomib in refractory or relapsed acute leukaemias. Clin Cancer Res 2004;10:3371-6.
24. Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud, D, et al. Plasma proteasome level is a potential marker in patients with solid tumours and hemopoietic malignancies. Cancer 2001;92:2493-500.
25. Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L, et al. Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Meth 2002;260:183-93.
26. Lightcap ES, Mc Cormack TA, Pin CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83.
27. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
28. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
29. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21.
30. Hirsch T, Dallaporta B, Zamzami N, Susin SA, Ravagnan L, Marzo I, et al. Proteasome activation occurs at an early, premitochondrial step of thymocyte apoptosis. J Immunol 1998;161:35-40.
31. Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000;96:269-74.